The Pill That Wants to Replace Your Needle
Pharvaris just posted Phase 3 data showing its once-daily oral pill can prevent hereditary angioedema attacks nearly as well as injectable drugs. The stock surged, analysts raised targets, and the rare disease world is paying attention.
Imagine you have a rare disease that causes unpredictable, painful swelling episodes. Your throat, your face, your gut. Now imagine the best prevention available requires you to stick yourself with a needle on a regular schedule, for the rest of your life.
That's the reality for people living with hereditary angioedema, or HAE. It's a genetic condition where the body produces too much bradykinin, a chemical that triggers severe swelling attacks. These attacks are painful, sometimes dangerous, and always disruptive. And until recently, managing them meant signing up for a life tethered to injectable drugs.
Pharvaris just dropped data suggesting that era might be ending.
An 83% Smackdown
The company's Phase 3 CHAPTER-3 trial tested deucrictibant, a once-daily oral pill designed to prevent HAE attacks. The results? An 83% reduction in monthly attack rate compared to placebo across the full study population. In patients with the two most common forms of the disease (types 1 and 2), the reduction climbed to 87%.
Every single secondary endpoint hit statistical significance too. That's the clinical trial equivalent of running the table in pool: you don't just win, you win convincingly.
Protection kicked in within the first week and held steady across the full 24-week treatment period. Patients weren't just having fewer attacks; a meaningful proportion became completely attack-free. The trial also showed strong responder rates at the ≥50%, ≥70%, and ≥90% thresholds, meaning this wasn't a story of modest improvement dragged up by a few outliers.
Why "Injectable-Like" Is the Magic Phrase
Pharvaris is calling this "injectable-like efficacy," and that framing is deliberate. The current gold standard for HAE prevention includes drugs like Takhzyro (lanadelumab) and Haegarda, both of which require injections. They work well, but they come with baggage: needle anxiety, injection-site pain, cold-chain storage, the hassle of prepping and administering doses.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
